ViaCell’s pipeline is focused in the area of reproductive health and on research and development of potential therapeutic uses of umbilical cord blood-derived stem cells.
ViaCell’s reproductive health business is responsible for marketing and sales of ViaCord Cord Blood Banking and the development of ViaCyte.
ViaCord
Preservation and storage of cord blood stem cells for related use
-
Over 130,000 units banked.
-
Sales totaled $54.1 million in 2006.
-
Significant opportunity for growth with total available market estimated at 30% of 4 million annual U.S. births.
ViaCyte
Preservation and storage of oocytes
Cardiac Disease
-
Pluripotent stem cells cultivated from umbilical cord blood.
-
Preclinical testing underway to evaluate dosing, delivery and targeting of USSCs with the NOGA XP delivery system for percutaneous delivery by interventional cardiologists.
-
No proven off-the-shelf therapy to repair or regenerate the heart after acute myocardial infarction or congestive heart failure.
Cancer
-
Cord blood-derived stem cells for use in hematopoietic transplantation.
-
Propriety technology in-licensed from Johns Hopkins for stem cell expansion.
-
Preclinical testing underway for potential use in treatment of blood cancers.
-
Addresses unmet medical need in transplantation where patients cannot find a bone marrow donor.
Diabetes